Provider of label-free drug discovery solutions, SAMDI Tech, has partnered with Enamine — supplier of drug-like screening compounds — to expand the number of molecules in their small-molecule compound libraries.
Partnership
“This partnership will provide us with the tools we need to continue to deliver increasingly comprehensive solutions to our clients,” said SAMDI Tech CEO Emilio Córdova, PhD, MBA. “With Enamine’s support, not only is it possible for researchers to screen for new leads against their novel targets, but our technology will allow them to narrow them down faster.”
Through this partnership, SAMDI Tech will be able to offer its clients access to more than half a million screening compounds. The team will be able to scree a client’s target, using its label-free and high-throughput assay, against any number of compounds. Once they get hits, Enamine will then provide support with the follow-up chemistry needed to validate and optimise the compound’s activity.
“We are proud to expand the reach of our compound collection through SAMDI Tech,” added Irina Yavnyuk, director of business development for Enamine.